{"id":4595,"date":"2025-03-31T18:12:13","date_gmt":"2025-03-31T18:12:13","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/octreotide-txt\/"},"modified":"2025-03-31T18:12:13","modified_gmt":"2025-03-31T18:12:13","slug":"octreotide-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/octreotide-txt\/","title":{"rendered":"octreotide.txt"},"content":{"rendered":"

CLINICAL USE <\/H3>
\nRelief of symptoms of gastroenteropancreatic endocrine tumours and acromegaly

DOSE IN NORMAL RENAL FUNCTION <\/H3>50 micrograms \u2013 1.2 mg daily

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :1019.2 (as acetate)<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :65<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 32<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :0.27<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :1.5\/Increased

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in normal renal function<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Dialysed. Dose as in normal renal function
  • HDF\/high flux &nbsp :Dialysed. Dose as in normal renal function
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Ciclosporin: ciclosporin concentration reduced

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>_

    Route <\/H4>SC, IV

    Rate of Administration <\/H4>IV bolus with ECG monitoring

    Comments<\/H4>IV: sodium chloride 0.9% to a ratio of not less than 1:1 and not more than 1:9

    OTHER INFORMATION <\/H4>SC: to reduce local discomfort, warm to room temperature before injectionFor multiple injections, use different sites Patients with reduced renal function have been shown to have a reduced clearance of the drug (75 mL\/minute vs. 175 mL\/minute).
    \n","protected":false},"excerpt":{"rendered":"

    CLINICAL USE Relief of symptoms of gastroenteropancreatic endocrine tumours and<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4595","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4595","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4595"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4595\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4595"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4595"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4595"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}